• 1
    Schiffman M,Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003; 127: 946949.
  • 2
    Ronco G,Giorgi-Rossi P,Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 2006; 7: 547555.
  • 3
    Goldie SJ,Kim JJ,Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004; 103: 619631.
  • 4
    Kulasingam SL,Hughes JP,Kiviat N, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002; 288: 17491757.
  • 5
    Schiffman M,Herrero R,Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000; 283: 8793.
  • 6
    Sarode VR,Werner C,Gander R, et al. Reflex human papillomavirus DNA testing on residual liquid-based (TPPT) cervical samples: focus on age-stratified clinical performance. Cancer (Cancer Cytopathol). 2003; 99: 149155.
  • 7
    Riethmuller D,Gay C,Bertrand X, et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol. 1999; 8: 157164.
  • 8
    Cope JU,Hildesheim A,Schiffman MH, et al. Comparison of the Hybrid Capture 2 test and PCR for detection of human papillomavirus DNA in cervical specimens. J Clin Microbiol. 1997; 35: 22622265.
  • 9
    Clavel C,Masure M,Putaud I, et al. Hybrid Capture II, a new sensitive test for human papillomavirus detection. Comparison with Hybrid Capture I and PCR results in cervical lesions. J Clin Pathol. 1998; 51: 737740.
  • 10
    Carozzi FM,Del Mistro A,Confortini M, et al. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting. Am J Clin Pathol. 2005; 124: 716721.
  • 11
    Castle PE,Wheeler CM,Solomon D, et al. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol. 2004; 122: 238245.
  • 12
    Negri G,Rigo B,Vittadello F, et al. Human papillomavirus typing with Hybrid Capture II on archived liquid-based cytologic specimens: is HPV typing always reproducible? Am J Clin Pathol. 2004; 122: 9093.
  • 13
    Jastania R,Geddie WR,Chapman W,Boerner S. Characteristics of apparently false-negative Digene Hybrid Capture 2 high-risk HPV DNA testing. Am J Clin Pathol. 2006; 125: 223228.
  • 14
    Zuna RE,Wang SS,Rosenthal DL, et al. Determinants of human papillomavirus-negative, low-grade squamous intraepithelial lesions in the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS). Cancer (Cancer Cytopathol). 2005; 105: 253262.
  • 15
    Newcombe R. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med. 1998; 17: 26352650.
  • 16
    Newcombe RG,Altman DG. Proporzioni e loro Differenze. In: AltmanDG,MachinD,BryantTN, et al, eds. Statistica Medica.2nd ed. Torino, Italy: Minerva Medica; 2004: 5256.
  • 17
    Muldrew KL,Beqaji SH,Han J, et al. Evaluation of a Digene-recommended algorithm for human papillomavirus low-positive results present in a “retest zone.” Am J Clin Pathol. 2007; 127: 97102.
  • 18
    Stoler MH,Castle PE,Solomon D,Shiffman, M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well- validated assays. Am J Clin Pathol. 2007; 127: 335337.